Company Overview
GeoVax Labs, Inc. operates as a clinical-stage biotechnology company dedicated to developing human vaccines and immunotherapies designed to combat infectious diseases and solid tumor cancers through the utilization of novel proprietary platforms. The entity functions within the broader Healthcare sector and specifically the Biotechnology industry, positioning itself as an innovator in preventive medicine and oncology research within the United States. This biotechnology firm maintains a market capitalization of $3.11M while generating total revenue of $3.35M over the trailing twelve months, supported by a workforce of 17 employees. The combination of a sub-$4M market cap and revenue figures that are nearly equivalent to the market cap value suggests the company is in a very early-stage development phase where valuation is driven primarily by potential pipeline value rather than established earnings or massive scale.
Financial Health
The company reported revenue of $3.35M for the trailing twelve months, yet it recorded a net income of $-25,309,002 and an EBITDA of $-25,469,526, revealing a cost structure where operating expenses significantly exceed revenue generation, which is typical for clinical-stage entities but indicates substantial financial burn. The company's free cash flow stands at $-14,961,973, which implies that the firm is consuming cash reserves to fund its research and development activities rather than generating surplus liquidity for shareholder returns or debt reduction. Margin analysis shows a gross margin of 0.0%, an operating margin of -761.6%, and a profit margin of 0.0%, collectively indicating that the company has not yet achieved profitability and that its current cost structure results in losses that are disproportionate to its current sales volume. On the balance sheet, GeoVax Labs holds cash of $5.01M against a debt level listed as N/A, and since no debt figure is provided, a specific debt-to-equity ratio cannot be calculated, but the existence of significant cash reserves suggests a conservative approach to leverage despite the lack of traditional debt obligations. The current ratio is 3.57, which indicates that the company possesses strong short-term liquidity, as it holds more than three and a half times the value of its current liabilities in assets. Finally, the return on equity is -377.4% and the return on assets is -178.9%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate significant losses rather than positive returns, a common characteristic of companies in the early phases of clinical trials.
Valuation Assessment
Valuation metrics for GeoVax Labs present a mixed picture, with a trailing P/E ratio of N/A due to negative earnings and a forward P/E of -1.63, implying that the market is pricing in future earnings expectations that differ significantly from historical performance or that the forward consensus assumes a rapid return to profitability. The price-to-book ratio is 0.34, which indicates that the stock is trading at a substantial discount to its book value, suggesting the market assigns a low premium to the company's tangible assets relative to its market capitalization. Alternative valuation measures include a price-to-sales ratio of 0.93 and an EV/EBITDA of 0.13, which suggests that the market is valuing the company at less than one dollar of revenue and less than one dollar of earnings power per dollar of enterprise value, reflecting high risk and low confidence in immediate cash flow generation. Regarding price volatility, the stock has a 52-week high of $35.25 and a 52-week low of $1.26; assuming a current price near the lower end of the recent trading range based on the forward P/E context, the stock is trading well below its 52-week high, potentially indicating a correction from previous speculative peaks or a prolonged period of underperformance relative to its historical maximum. The beta value is 3.88, which means the stock price is nearly four times more volatile than the broader market, exposing investors to extreme swings in share price that are magnified during periods of market stress or biotechnology sector turbulence.
Growth & Income
Growth rates for both revenue and earnings are listed as N/A, indicating that the company has not yet established a track record of year-over-year expansion or consistent earnings growth, which is consistent with a clinical-stage business model focused on product development rather than sales scaling. Since the company reports a net income of $-25,309,002, it is not a dividend payer, resulting in a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all available cash flow, however negative, into its research platforms rather than distributing income to shareholders. The absence of dividends and the negative earnings growth imply that the company's primary strategy is to exhaust its $5.01M cash reserve to advance its vaccine and immunotherapy platforms toward clinical milestones rather than generating shareholder income. Overall, the growth and income profile of GeoVax Labs is characterized by a complete reliance on capital preservation and reinvestment for future potential, with no current mechanism for generating income for investors.